MOLOGEN AG completes capital increase from authorized capital; gross proceeds of EUR 8,151,422

MOLOGEN AG / Key word(s): Capital Increase

MOLOGEN AG completes capital increase from authorized capital; gross proceeds of EUR 8,151,422

26-Sep-2018 / 16:52 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Publication of an inside information pursuant to Section 17 of the regulation (EU) No. 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG completes capital increase from authorized capital; gross proceeds of EUR 8,151,422

Berlin, 26 September 2018 – MOLOGEN AG (ISIN DE000A2LQ900, WKN A2LQ90) placed new shares from the cash capital increase resolved on 1 September 2018 with indirect subscription rights of the existing shareholders and subsequent international private placement with qualified investors in the amount of 1,734,345 shares (corresponds to 23% of the currently existing share capital). The purchase price in the context of the private placement was fixed at EUR4.70 per new share and thus corresponds to the subscription price for existing shareholders. The Company’s share capital will therefore be increased from EUR7,537,287 by EUR1,734,345 to EUR9,271,632 by issuing 1,734,345 new bearer ordinary shares with a proportional amount in the share capital of EUR1.00 per share for contribution in cash.

The gross proceeds of EUR8,151,422 will be fully used for the further funding of the ongoing pivotal IMPALA clinical study with lefitolimod in the indication of colorectal cancer and for the production of further clinical medication. With the cash available and the funds from the capital increase, the Company would be financed until mid-2019. Together with the potential contribution from MOLOGEN’s partner ONCOLOGIE and potential further financing (e.g. the utilization of the existing capital instruments) the Phase III IMPALA clinical study would be financed up to the expected time of the read-out.

The Executive Board will shortly apply for the registration of the implementation of the capital increases with the commercial register; the inclusion of the new shares under the Company’s existing listing (ISIN DE000A2LQ900, SIN A2L Q90) is planned for 4 October 2018.

Important note:
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

This release is not a prospectus. Investors should not purchase or subscribe for any shares referred to in this press release except on the basis of information in a prospectus to be issued by the Company in connection with the offering of such shares. This release is not an offer of securities for sale in the United States of America. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration or in a transaction not subject to the registration requirements of the Securities Act. There will be no public offer of the securities in the United States of America.

Subject to certain exceptions under the Securities Act, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

– End of the ad-hoc notification –

Contact

Claudia Nickolaus

Head of Investor Relations & Corporate Communications
Tel: +49 – 30 – 84 17 88 – 38
Fax: +49 – 30 – 84 17 88 – 50
investor@mologen.com

Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.


26-Sep-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE000A2LQ900
WKN: A2LQ90
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this